LUND, Sweden, June 9, 2025 — Hansa Biopharma AB (“Hansa”) (Nasdaq Stockholm: HNSA) has announced that it will hold a virtual investor event focused on Guillain-Barré syndrome (GBS) on Monday, June 16, 2025, at 2:00 PM CEST / 8:00 AM EDT. Registration in advance is required and can be completed at [link].

Presentations from Dr. David R. Cornblath, MD, of Johns Hopkins University School of Medicine, and Dr. Simon Rinaldi MRCP (Neuro), PhD, of the University of Oxford, will cover the existing treatment options and the unmet needs for GBS, a rare, acute, inflammatory disease affecting the peripheral nervous system and causing paralysis. They will also discuss the function of Immunoglobulin G (IgG) in GBS and recent scientific and research advancements.

Company executives, including Hitto Kaufmann, Chief R&D Officer, and Elisabeth Sonesson, VP, Global Franchise Lead Autoimmunity, will provide updates on the Company’s current activities and upcoming milestones in the autoimmune field.

A live question and answer session will follow the presentations. This event is the first in a series of Science Deep Dive virtual events tailored for investors, focusing on Hansa’s key therapeutic areas: Autoimmune diseases, Gene Therapy, and Kidney Transplantation.

About David R. Cornblath, MD

Dr. David Cornblath earned his medical degree from Case Western Reserve University and completed an internship at University Hospitals in Cleveland, Ohio, followed by a neurology residency at the Hospital of the University of Pennsylvania. He was a Clinical Fellow of the Muscular Dystrophy Association at the Peripheral Nerve Morphology Laboratory before joining the faculty at Johns Hopkins. He rose to the rank of Professor and served as Director of the Neurology EMG Laboratory. Currently retired, Dr. Cornblath remains active as a consultant, participating in safety monitoring boards and clinical trial development programs. He also holds the title of Professor Emeritus of Neurology at Johns Hopkins.

About Simon Rinaldi, MRCP(Neuro), PhD

Dr. Simon Rinaldi is a clinical neurologist and scientist who heads the inflammatory neuropathy research program at the University of Oxford. His research ranges from in vitro disease modeling using cell-based assays to biomarker discovery, clinical phenotyping, and clinical trials. His lab has created models of immune-mediated axonal injury and demyelination using myelinating co-cultures derived from human induced pluripotent stem cells. These experimental systems are now used to gain insights into the mechanisms of immune-mediated peripheral nerve injury and are valuable tools for identifying novel auto-antibodies and for the discovery and pre-clinical assessment of fluid biomarkers. The lab also operates the only UK-based diagnostic testing service for nodal and paranodal antibodies, which are linked to specific types of autoimmune nodopathy. The underlying B-cell biology of these and related peripheral nerve disorders is a more recent focus of study. His research program also includes Bio-SPiN, a clinical/observational study of chronic inflammatory neuropathy. The group also benefits from and contributes to close relationships with the comprehensive clinical-serological database of 2000 patients within the International GBS Outcome Study (IGOS) and has been involved in therapeutic trials for Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and multifocal motor neuropathy (MMN).

Conference call details

To register and submit questions beforehand, please follow this link: [link]

To join the telephone conference, please use the following dial-in information:

Participant Dial In (Toll Free): 1-833-821-3542

Participant International Dial In: 1-412-652-1248

The webcast will be accessible at: [link]

Contacts for more information:

Evan Ballantyne, Chief Financial Officer

Stephanie Kenney, VP Global Corporate Affairs

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering biopharmaceutical company in the commercial stage focused on developing and marketing innovative therapies that can save and transform the lives of patients with rare immunological conditions. The company has an extensive research and development program built upon its unique IgG-cleaving enzyme technology platform, aimed at addressing significant unmet needs in autoimmune diseases, gene therapy, and transplantation. The company’s offerings include imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, proven to facilitate kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule that allows for redosing. Hansa Biopharma is headquartered in Lund, Sweden, with operations across Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. For more information, visit [website] and follow us on [social media].

©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This announcement was issued by Cision.

The following files are available for download:

“`